For sickle cell disease. Sold as Adakveo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Crizanlizumab-Tmca (sold as Adakveo), first approved Nov 15, 2019, with 1 new use approved and 0 published complete response letters.
| Adakveo | Part B | $26.0M | +0% | 424 |
| Adakveo | Part D | $5.5M | +11% | 84 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesAdvanced Glioblastoma, Metastatic Melanoma in the Central Nervous System · Sheba Medical Center | Phase 2 | Recruiting | Jun 18, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 15, 2019 | AdakveoBLA 761128 · New molecular entity | Novartis Pharms Corp | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
